Drugs Made In America Acquisition Corp. (DMAAR) Net Cash Flow (2025)

Drugs Made In America Acquisition (DMAAR) has reported Net Cash Flow for 1 consecutive years, with $5420.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow changed N/A year-over-year to $5420.0; the trailing twelve-month figure through Dec 2025 stood at $4786.0 (changed N/A YoY), and the FY2025 full-year result was $4786.0, up 254.26% from the prior year.
• Net Cash Flow rose to $5420.0 in Q4 2025 per DMAAR's latest filing, from -$105.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $5420.0 in Q4 2025 and bottomed at -$428.0 in Q1 2025.